Bone, Basal Metabolism Link Depends on Vitamin D Level

This article originally appeared here.
Share this content:
Bone, Basal Metabolism Link Depends on Vitamin D Level
Bone, Basal Metabolism Link Depends on Vitamin D Level

WEDNESDAY, April 5, 2017 (HealthDay News) -- For postmenopausal women with type 2 diabetes mellitus (T2DMPW), the correlation between bone metabolism and basal metabolism seems to be dependent on serum 25-hydroxyvitamin D (25[OH]D) levels, according to a study published online March 31 in the Journal of Diabetes Investigation.

Makiko Ogata, from the Tokyo Women's Medical University School of Medicine, and colleagues enrolled 44 T2DMPW in a prospective follow-up study performed with vitamin D supplementation. Twenty-three patients with low 25(OH)D levels were told to increase vitamin D levels by lifestyle change. Alfacalcidol was administered to 15 patients with osteoporosis.

The researchers found that serum 25(OH)D increased and decreased in 25 and 19 patients, respectively. A decrease in 25(OH)D was seen for patients who did not receive the study intervention at the start. There was a positive correlation between changes in resting energy expenditure and those of procollagen type 1 N-terminal propeptide (P1NP)/carboxy-terminal collagen crosslinks-1. There was a correlation for changes in respiratory quotient with mean glycated hemoglobin levels; after the intervention P1NP correlated positively with serum 25(OH)D. The correlations were prominent in those with increased 25(OH)D and alfacalcidol supplementation.

"Restoration of vitamin D level may be a prerequisite for a normal correlation between bone and basal metabolism in T2DMPW," the authors write.

Several authors disclosed financial ties to the pharmaceutical industry.

Abstract
Full Text

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions

More in Home

FDA Approves Kinase Inhibitor for Treatment of AML

FDA Approves Kinase Inhibitor for Treatment of AML

Midostaurin, in combination with chemotherapy, treats acute myeloid leukemia in adults

Enzyme Replacement Drug OK'd for Form of Batten Disease

Enzyme Replacement Drug OK'd for Form of Batten ...

Brineura will be used to treat children with late infantile neuronal ceroid lipofuscinosis type 2 Batten

is free, fast, and customized just for you!

Already a member?

Sign In Now »